CoChat

Repetitive transcranial magnetic stimulation may be a cost‐effective alternative to antidepressant therapy after two treatment failures in patients with major depressive disorder

Open access
Zemplényi, Antal, Józwiak-Hagymásy, Judit, Kovács, Sándor, Erdősi, Dalma, Boncz, Imre, Tényi, Tamás, Osváth, Péter, Voros, Viktor · 2022 · BMC Psychiatry

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Background: The cost-effectiveness of treatment strategies for patients with Major Depressive Disorder (MDD) who have not responded to two adequate treatments with antidepressants (TRD) are still unclear. The aim of this analysis was to evaluate the cost-effectiveness of add-on repetitive Transcranial Magnetic Stimulation (rTMS) compared with standard treatment. Methods: A Markov-model simulated clinical events over one year from the perspective of healthcare payer. Third- and fourth-line treatment pathways (augmentation, antidepressant switch or combination, and Electro-Convulsive Therapy (ECT)) were defined based on medical practice guidelines. Transition probabilities were derived from a recent meta-analysis and scientific publications. Resource utilization and cost estimates were based on the patient-level database of a large university hospital. Results: Incremental Quality-Adjusted Life Years (QALYs) and costs were 0.053 and 785 €, respectively, corresponding to an Incremental Cost-Effectiveness Ratio (ICER) of 14,670 € per QALY. The difference in cost between standard treatment and rTMS is explained by the rTMS sessions used in acute (€660) and maintenance (€57/month) treatments, partly offset by lower hospital costs due to higher remission rates in the rTMS arm. Key parameters driving the ICER were incremental utility of remission, unit cost of rTMS treatment and remission rate. At a threshold of €22,243 add-on rTMS is a cost-effective alternative to pharmacotherapy. Evidence on long-term effectiveness is not yet available, so results are estimated for a one-year period. Conclusion: Not only does rTMS treatment have beneficial clinical effects compared with drug therapy in TRD, but it also appears to offer good value-for-money, especially in centres with larger numbers of patients where unit costs can be kept low.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12888-022-04078-9

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Markov-model structure for the health states and the transitions in the cost-effectiveness analysis
Fig. 1 Markov-model structure for the health states and the transitions in the cost-effectiveness analysisCC BY · PubMed Central
Fig. 2 Result of the deterministic sensitivity analysis
Fig. 2 Result of the deterministic sensitivity analysisCC BY · PubMed Central
Fig. 3 Cost-effectiveness plane (add-on rTMS vs. standard of care)
Fig. 3 Cost-effectiveness plane (add-on rTMS vs. standard of care)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Research works printed but not linked: 2

  1. Rihmer Z, Szili I, Kalabay L, Torzsa P. A depresszió és öngyilkossági veszély szűrése a háziorvosi és általános orvosi gyakorlatban. LAM. 2017;27:17–24.
  2. Döme P, Rihmer Z, Bitter I, Gonda X, Herold R, Kurimay T, et al. Major (unipolar) depressive disorder: diagnostic and therapeutic guidelines. Egészségügyi Közlöny (In Hungarian). 2021;71:970–1031.

Cited by

See all 25

Metadata

Authors
Zemplényi, A., Józwiak-Hagymásy, J., Kovács, S., Erdősi, D., Boncz, I., Tényi, T., Osváth, P., & Voros, V.
Affiliations
University of Pecs (HU)
Venue
BMC Psychiatry
Published
2022-06-28
Volume
22
Issue
1
Pages
437-437
ISSN
1471-244X (ISSN-L)
OpenAlex
W4283640491
Cited by
23
References
38
Citations by year
2026: 4 · 2025: 6 · 2024: 10 · 2023: 3
FWCI
1.67
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
University of Pécs
Topics
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
repetitive transcranial magnetic stimulation, major depressive disorder, treatment-resistant depression, cost-effectiveness, antidepressant treatment, adjunctive therapy, quality-adjusted life years, incremental cost-effectiveness ratio, remission, electroconvulsive therapy, Markov model
MeSH terms
Antidepressive Agents, Cost-Benefit Analysis, Depressive Disorder, Major, Major Depressive Disorder, Electroconvulsive Therapy, Humans, Treatment Failure, Transcranial Magnetic Stimulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Repetitive transcranial magnetic stimulation may be a cost‐effective alternative to antidepressant therapy after two treatment failures in patients with major depressive disorder. https://app.cochat.ai/papers/10.1186/s12888-022-04078-9
The paper
Zemplényi, A., Józwiak-Hagymásy, J., Kovács, S., Erdősi, D., Boncz, I., Tényi, T., Osváth, P., & Voros, V. (2022). Repetitive transcranial magnetic stimulation may be a cost‐effective alternative to antidepressant therapy after two treatment failures in patients with major depressive disorder. BMC Psychiatry. https://doi.org/10.1186/s12888-022-04078-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.